Trial
NCT04638153
A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Pfizer
Collaborators
—
Condition
Achondroplasia
Intervention
Recifercept
Why stopped
The study was terminated due to lack of efficacy at any of the tested doses on 18th November 2022. The decision to terminate the study is not related to a safety concern.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-02-15